RISK OF SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS (CROSBI ID 695218)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Vlak, Tonko
engleski
RISK OF SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS
Objective:Rheumatoid arthritis is most frequently associatedwith development of sarcopenia among chronic inflammatorydisease group. Risk of adverse outcomes, such as physicaldisability, poor quality of life and higher mortality rates, inrheumatoid arthritis is increasing with the development ofsarcopenia. Therefore, we performed systematic literaturesearch to provide closer look in causal factors and risks fordevelopment of sarcopenia.Methods:A systematic literature search was carried out inMEDLINE ; Cochrane Library, PEDro and ACR/EULARmeeting abstracts.Results:Although the exact mechanisms for sarcopenia de-velopment in rheumatoid arthritis still remains to be elucidat-ed, several factor have been proposed such as increased pro-duction of pro-inflammatory cytokines, mainly tumor necrosisfactor-alpha and interleukin-1 beta, hormonal changes, oxida-tive damage, reduced protein synthesis in myocytes, insulinresistance, inadequate protein ingestion, physical activity lim-itation and pain. Furthermore, it is shown that somereumathoid arthritis associated disease and treatment charac-teristics can also contribute to development of sarcopenia suchas: increasing joint deformity, self-reported disability scores, C-reactive protein levels, rheumatoid factor seropositivity, anda lack of current treatment with disease-modifying antirheu-matic drugs. Sex and age differences should also be taken in toaccount when considering body composition phenotypes ofrheumatoid arthritis. The good news is that most of abovementioned factors could be alleviated but in order to start withthe treatment of sarcopenia we have to be aware of high prev-alence of sarcopenia among rheumatoid arthritis patients andimprove clinical detection tools.Conclusion:Risk of sarcopenia development in rheumatoidarthritis is rather high and can have devastating consequenceson quality of life, morbidity and mortality. In the managementS146Osteoporos Int (2018) 29 (Suppl 1):S109–S147 of rheumatoid arthritis patients, we should consider preven-tion and treatment of sarcopenia as one of main strategies.
Rheumatic Arthritis ; Sarcopenia
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
146-147.
2018.
objavljeno
10.1007/s00198-018-4439-3
Podaci o matičnoj publikaciji
London : Delhi: Springer Science+Business Media
0937-941X
Podaci o skupu
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018)
predavanje
19.04.2018-22.04.2018
Kraków, Poljska
Povezanost rada
Kliničke medicinske znanosti